Artivion Inc (AORT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances [Yahoo! Finance]
Artivion, Inc. (AORT)
Company Research
Source: Yahoo! Finance
Adjusted EBITDA Margin: 18.5%, a 270 basis point improvement over the prior year. On-X Revenue Growth: 15% year-over-year on a constant currency basis. BioGlue Revenue Growth: 14% year-over-year on a constant currency basis. Stent Graft Revenue Growth: 13% year-over-year on a constant currency basis. Tissue Processing Revenue Growth: 2% year-over-year on a constant currency basis. Gross Margin: 64%, flat compared to Q3 2023. Free Cash Flow: $7.8 million in Q3 2024. Cash and Debt: $56.2 million in cash and $314 million in debt as of September 30, 2024. Net Leverage: 3.9x, down from 5.3x in prior years. Regional Revenue Growth: Latin America 32%, Asia Pacific 23%, EMEA 15%, North America 2% year-over-year. Warning! GuruFocus has detected 5 Warning Sign with AORT. Release Date: November 07, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Artivion Inc ( NYSE:AORT ) reported a robust revenue growth of 10% y
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- Artivion, Inc. (NYSE: AORT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $30.00 to $32.00. They now have an "outperform" rating on the stock.MarketBeat
- Artivion Reports Third Quarter 2024 Financial ResultsPR Newswire
- Artivion to Participate in Upcoming Investor ConferencesPR Newswire
- Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2024 Financial ResultsPR Newswire
- Artivion started at market outperform by JMP, stent graft devices cited [Seeking Alpha]Seeking Alpha
AORT
Earnings
- 11/7/24 - Beat
AORT
Sec Filings
- 11/8/24 - Form 10-Q
- 11/8/24 - Form SC
- 11/8/24 - Form SC
- AORT's page on the SEC website